Analyst Update: Kohl's, Skyworks, Coronado Biosciences

Analysts adjusted their ratings on Kohl's Corporation (KSS), Skyworks Solutions Inc (SWKS), and Coronado Biosciences Inc (CNDO)

Mar 31, 2015 at 11:49 AM
facebook twitter linkedin


Analysts are weighing in today on retailer Kohl's Corporation (NYSE:KSS), semiconductor issue Skyworks Solutions Inc (NASDAQ:SWKS), and biotech firm Coronado Biosciences Inc (NASDASQ:CNDO). Here's a quick look at today's brokerage notes on KSS, SWKS, and CNDO.

  • KSS is up 2.7% to $78.68 -- and earlier touched a near-eight-year high of $78.80 -- after Sterne Agee raised its price target on the equity to $85 while keeping its "buy" rating. The hike comes as no surprise, considering the shares of Kohl's Corporation have advanced 28.9% year-to-date. Despite this impressive price action, short sellers have taken a shine to the stock, as short interest increased by about 9.7% over the past two reporting periods. As of right now, 12.07% of KSS' available float is sold short, which would take almost two weeks to cover, at average trading volumes. Should KSS extend its quest for new highs, a short squeeze could add fuel to the stock's fire.

  • Raymond James raised its price target on SWKS by $12 to $117 -- in uncharted territory. The stock is still feeling the effects of last week's sector-wide swoon, down 1.2% today to hit $98.97. Looking back, though, Skyworks Solutions Inc has been a technical juggernaut, with the shares up 163.1% year-over-year. In fact, the equity notched an all-time high of $102.77 just last week. However, sentiment in the options pits has been bearish, as SWKS's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.45 ranks higher than 88% of all equivalent readings taken over the past year. On the other hand, the brokerage bunch remains extremely bullish on SWKS, as 86% of covering analysts rate the security a "strong buy."

  • CNDO is up 17.5% to $4.16, after MLV & Co upgraded the stock to "buy" from "hold," while increasing its price target to $7 from $2. What's more, the brokerage firm said it expects Coronado Biosciences Inc's opioid drug, tramadol, to win regulatory approval as early as next year, and estimated the drug could generate $80 million in annual sales by 2018. On the charts, CNDO has been a technical outperformer of late, with the shares up about 70% year-to-date, and just off an annual high of $5.35, tagged earlier this month. However, puts have been prominent in the options pits, as CNDO's 50-day ISE/CBOE/PHLX put/call volume ratio of 0.11 stands in the 80th percentile of its annual range. Simply stated, traders have been buying puts over calls at a faster-than-usual clip.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

 


 


 
Special Offers from Schaeffer's Trading Partners